194 related articles for article (PubMed ID: 27897410)
1. Androgen deprivation causes selective deficits in the biomechanical leg muscle function of men during walking: a prospective case-control study.
Cheung AS; Gray H; Schache AG; Hoermann R; Lim Joon D; Zajac JD; Pandy MG; Grossmann M
J Cachexia Sarcopenia Muscle; 2017 Feb; 8(1):102-112. PubMed ID: 27897410
[TBL] [Abstract][Full Text] [Related]
2. Biomechanical Leg Muscle Function During Stair Ambulation in Men Receiving Androgen Deprivation Therapy.
Cheung AS; Gray HA; Schache AG; Hoermann R; Bicknell J; Joon DL; Zajac JD; Pandy MG; Grossmann M
J Gerontol A Biol Sci Med Sci; 2020 Sep; 75(9):1715-1722. PubMed ID: 31310271
[TBL] [Abstract][Full Text] [Related]
3. Selective Loss of Levator Ani and Leg Muscle Volumes in Men Undergoing Androgen Deprivation Therapy.
Cheung AS; Cunningham C; Ko DD; Ly V; Gray H; Hoermann R; Strauss BJG; Bani Hassan E; Duque G; Ebeling P; Pandy MG; Zajac JD; Grossmann M
J Clin Endocrinol Metab; 2019 Jun; 104(6):2229-2238. PubMed ID: 30602021
[TBL] [Abstract][Full Text] [Related]
4. Contributions to the understanding of gait control.
Simonsen EB
Dan Med J; 2014 Apr; 61(4):B4823. PubMed ID: 24814597
[TBL] [Abstract][Full Text] [Related]
5. Does Use of Androgen Deprivation Therapy (ADT) in Men with Prostate Cancer Increase the Risk of Sarcopenia?
Owen PJ; Daly RM; Dalla Via J; Mundell NL; Livingston PM; Rantalainen T; Fraser SF
Calcif Tissue Int; 2019 Oct; 105(4):403-411. PubMed ID: 31317232
[TBL] [Abstract][Full Text] [Related]
6. Evidence for reduced neuromuscular function in men with a history of androgen deprivation therapy for prostate cancer.
Girard D; Marino FE; Cannon J
Clin Physiol Funct Imaging; 2014 May; 34(3):209-17. PubMed ID: 24119067
[TBL] [Abstract][Full Text] [Related]
7. The clinical relevance of adiposity when assessing muscle health in men treated with androgen deprivation for prostate cancer.
Owen PJ; Daly RM; Dalla Via J; Mundell NL; Livingston PM; Rantalainen T; Fraser SF
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1036-1044. PubMed ID: 31067013
[TBL] [Abstract][Full Text] [Related]
8. Persisting adverse body composition changes 2 years after cessation of androgen deprivation therapy for localised prostate cancer.
Cheung AS; Tinson AJ; Milevski SV; Hoermann R; Zajac JD; Grossmann M
Eur J Endocrinol; 2018 Jul; 179(1):21-29. PubMed ID: 29712718
[TBL] [Abstract][Full Text] [Related]
9. Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer.
Taaffe DR; Buffart LM; Newton RU; Spry N; Denham J; Joseph D; Lamb D; Chambers SK; Galvão DA
BJU Int; 2018 Feb; 121(2):194-202. PubMed ID: 28872752
[TBL] [Abstract][Full Text] [Related]
10. Moderators of resistance-based exercise programs' effect on sarcopenia-related measures in men with prostate cancer previously or currently undergoing androgen deprivation therapy: An individual patient data meta-analysis.
Lopez P; Newton RU; Taaffe DR; Winters-Stone K; Galvão DA; Buffart LM
J Geriatr Oncol; 2023 Jun; 14(5):101535. PubMed ID: 37229882
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of androgen deprivation therapy in prostate cancer patients.
Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
[TBL] [Abstract][Full Text] [Related]
12. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
13. Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer.
Cheung AS; Hoermann R; Dupuis P; Joon DL; Zajac JD; Grossmann M
Eur J Endocrinol; 2016 Sep; 175(3):229-37. PubMed ID: 27340081
[TBL] [Abstract][Full Text] [Related]
14. Effects of androgen deprivation therapy on elderly men with high-risk prostate cancer: PROSARC observational study.
Legido-Gómez Ó; Rico-Marco S; Lorenzo-Sánchez MV; Navarro-Jiménez S; Tárraga-Honrubia MA; Martínez-Ruiz J; Giménez-Bachs JM; Donate-Moreno MJ; Díaz de Mera-Sánchez-Migallón I; Segura-Martín M; Alcantud-Córcoles R; Abizanda-Soler P; Salinas-Sánchez AS
Actas Urol Esp (Engl Ed); 2024 May; 48(4):304-310. PubMed ID: 38373481
[TBL] [Abstract][Full Text] [Related]
15. HoSAGE: Sarcopenia in Older Patients before and after Treatment with Androgen Deprivation Therapy and Radiotherapy for Prostate Cancer.
Couderc AL; Muracciole X; Nouguerede E; Rey D; Schneider S; Champsaur P; Lechevallier E; Lalys L; Villani P
J Nutr Health Aging; 2020; 24(2):205-209. PubMed ID: 32003412
[TBL] [Abstract][Full Text] [Related]
16. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
[TBL] [Abstract][Full Text] [Related]
17. Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer.
Chang D; Joseph DJ; Ebert MA; Galvão DA; Taaffe DR; Denham JW; Newton RU; Spry NA
J Med Imaging Radiat Oncol; 2014 Apr; 58(2):223-8. PubMed ID: 24118850
[TBL] [Abstract][Full Text] [Related]
18. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition.
Taaffe DR; Galvão DA; Spry N; Joseph D; Chambers SK; Gardiner RA; Hayne D; Cormie P; Shum DHK; Newton RU
BJU Int; 2019 Feb; 123(2):261-269. PubMed ID: 30239116
[TBL] [Abstract][Full Text] [Related]
19. After scaling to body size hip strength of the residual limb exceeds that of the intact limb among unilateral lower limb prosthesis users.
Sawers A; Fatone S
J Neuroeng Rehabil; 2023 Apr; 20(1):50. PubMed ID: 37098570
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the FC prostate randomised controlled trial.
Uth J; Hornstrup T; Christensen JF; Christensen KB; Jørgensen NR; Schmidt JF; Brasso K; Jakobsen MD; Sundstrup E; Andersen LL; Rørth M; Midtgaard J; Krustrup P; Helge EW
Osteoporos Int; 2016 Apr; 27(4):1507-1518. PubMed ID: 26572756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
